https://biopharmaperspective.com/about/ 2025-10-30T15:22:16Z https://biopharmaperspective.com/wp-content/uploads/2025/10/about-image_1.png https://biopharmaperspective.com/pharma-trends/ 2025-10-31T14:59:07Z https://biopharmaperspective.com/wp-content/uploads/2025/10/pharma-trends-image.png https://biopharmaperspective.com/2025/10/30/home/ 2025-10-31T15:43:18Z https://biopharmaperspective.com/wp-content/uploads/2025/10/eba994ec9db8ed9994eba9b4-image.png https://biopharmaperspective.com/2025/10/30/home/ 2025-10-31T15:47:30Z https://biopharmaperspective.com/wp-content/uploads/2025/10/main-image.png https://biopharmaperspective.com/wellness/ 2025-10-31T15:54:27Z https://biopharmaperspective.com/wp-content/uploads/2025/11/wellness-image.png https://biopharmaperspective.com/wellness/ 2025-10-31T15:56:41Z https://biopharmaperspective.com/wp-content/uploads/2025/11/wellness-image-1.png https://biopharmaperspective.com/2025/10/30/home/ 2025-10-31T16:02:58Z https://biopharmaperspective.com/wp-content/uploads/2025/10/main-image-1.png https://biopharmaperspective.com/2025/11/01/key-pharma-biotech-trends-that-defined-2025/ 2025-10-31T16:17:14Z https://biopharmaperspective.com/wp-content/uploads/2025/11/ecb2abebb288eca7b8-ed8facec8aa4ed8c85-ec9db4ebafb8eca780.png https://biopharmaperspective.com/2025/11/01/key-pharma-biotech-trends-that-defined-2025/ 2025-10-31T16:22:31Z https://biopharmaperspective.com/wp-content/uploads/2025/11/image.png https://biopharmaperspective.com/2025/11/01/fda-and-hhs-announce-biosimilar-reform-no-more-comparative-trials-full-interchangeability-ahead/ 2025-11-01T06:29:26Z https://biopharmaperspective.com/wp-content/uploads/2025/11/eb9190ebb288eca7b8-ed8facec8aa4ed8c85-ec9db4ebafb8eca780_ec9888ebb984.png https://biopharmaperspective.com/2025/11/01/fda-and-hhs-announce-biosimilar-reform-no-more-comparative-trials-full-interchangeability-ahead/ 2025-11-01T06:33:29Z https://biopharmaperspective.com/wp-content/uploads/2025/11/eb9190ebb288eca7b8-ed8facec8aa4ed8c85-ebb3b8ebacb8ec9aa9.jpg https://biopharmaperspective.com/2025/11/02/americas-100-drug-import-tariff-reshaping-pharma-patents-and-patients/ 2025-11-02T05:58:18Z https://biopharmaperspective.com/wp-content/uploads/2025/11/3-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/03/the-battle-for-metsera-pfizer-and-novo-nordisk-in-a-fierce-takeover-war/ 2025-11-03T13:19:07Z https://biopharmaperspective.com/wp-content/uploads/2025/11/4-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/03/the-battle-for-metsera-pfizer-and-novo-nordisk-in-a-fierce-takeover-war/ 2025-11-03T13:19:56Z https://biopharmaperspective.com/wp-content/uploads/2025/11/4-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/04/eli-lillys-major-netherlands-plant-investment-scaling-supply-for-oral-obesity-therapy/ 2025-11-04T13:05:30Z https://biopharmaperspective.com/wp-content/uploads/2025/11/5-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/04/eli-lillys-major-netherlands-plant-investment-scaling-supply-for-oral-obesity-therapy/ 2025-11-04T13:21:28Z https://biopharmaperspective.com/wp-content/uploads/2025/11/5-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/05/bidding-war-heats-up-pfizer-vs-novo-nordisk-in-the-race-to-acquire-metsera/ 2025-11-05T14:52:11Z https://biopharmaperspective.com/wp-content/uploads/2025/11/6-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/05/bidding-war-heats-up-pfizer-vs-novo-nordisk-in-the-race-to-acquire-metsera/ 2025-11-05T14:52:52Z https://biopharmaperspective.com/wp-content/uploads/2025/11/6-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/07/lilly-novo-nordisk-reach-landmark-pricing-agreement-with-u-s-government-on-obesity-drugs/ 2025-11-07T11:23:07Z https://biopharmaperspective.com/wp-content/uploads/2025/11/7-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/07/lilly-novo-nordisk-reach-landmark-pricing-agreement-with-u-s-government-on-obesity-drugs/ 2025-11-07T11:23:28Z https://biopharmaperspective.com/wp-content/uploads/2025/11/7-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/09/pfizer-lands-metsera-acquisition-after-novo-nordisk-bows-out-of-10-b-bidding-war/ 2025-11-08T16:31:02Z https://biopharmaperspective.com/wp-content/uploads/2025/11/8-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/09/pfizer-lands-metsera-acquisition-after-novo-nordisk-bows-out-of-10-b-bidding-war/ 2025-11-08T16:31:42Z https://biopharmaperspective.com/wp-content/uploads/2025/11/8-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/11/eli-lilly-advances-obesity-drug-pipeline-after-positive-phase-2-results/ 2025-11-10T15:00:55Z https://biopharmaperspective.com/wp-content/uploads/2025/11/9-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/11/eli-lilly-advances-obesity-drug-pipeline-after-positive-phase-2-results/ 2025-11-10T15:01:30Z https://biopharmaperspective.com/wp-content/uploads/2025/11/9-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/11/eli-lilly-advances-obesity-drug-pipeline-after-positive-phase-2-results/ 2025-11-10T15:02:01Z https://biopharmaperspective.com/wp-content/uploads/2025/11/9-ebb3b8ebacb8ec9aa9-1.png https://biopharmaperspective.com/2025/11/11/eli-lilly-strikes-475-m-gene-therapy-deal-with-meiragtx-for-rare-retinal-disease/ 2025-11-11T12:38:42Z https://biopharmaperspective.com/wp-content/uploads/2025/11/10-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/11/eli-lilly-strikes-475-m-gene-therapy-deal-with-meiragtx-for-rare-retinal-disease/ 2025-11-11T12:43:37Z https://biopharmaperspective.com/wp-content/uploads/2025/11/10-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2025/11/12/novo-nordisks-wegovy-shows-liver-health-benefits-beyond-weight-loss-in-mash-patients/ 2025-11-12T12:46:38Z https://biopharmaperspective.com/wp-content/uploads/2025/11/11-ec8db8eb84a4ec9dbc.png https://biopharmaperspective.com/2025/11/12/novo-nordisks-wegovy-shows-liver-health-benefits-beyond-weight-loss-in-mash-patients/ 2025-11-12T12:54:52Z https://biopharmaperspective.com/wp-content/uploads/2025/11/11-ebb3b8ebacb8ec9aa9.png https://biopharmaperspective.com/2026/07/26/can-gsks-oncology-and-hiv-strategy-deliver-its-40-billion-revenue-goal-by-2031/ 2026-07-26T01:18:44Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260726_thumbnail.png https://biopharmaperspective.com/2026/07/26/can-gsks-oncology-and-hiv-strategy-deliver-its-40-billion-revenue-goal-by-2031/ 2026-07-26T01:26:06Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260726_thumbnail-1.png https://biopharmaperspective.com/2026/07/26/can-gsks-oncology-and-hiv-strategy-deliver-its-40-billion-revenue-goal-by-2031/ 2026-07-26T01:22:20Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260726_image1.png https://biopharmaperspective.com/2026/07/26/can-gsks-oncology-and-hiv-strategy-deliver-its-40-billion-revenue-goal-by-2031/ 2026-07-27T09:46:46Z https://biopharmaperspective.com/wp-content/uploads/2026/07/bp-image.png https://biopharmaperspective.com/bp-logo/ 2026-07-27T09:47:29Z https://biopharmaperspective.com/wp-content/uploads/2026/07/bp-logo.png https://biopharmaperspective.com/bp-logo/ 2026-07-27T09:47:37Z https://biopharmaperspective.com/wp-content/uploads/2026/07/cropped-bp-logo.png https://biopharmaperspective.com/bp-logo/ 2026-07-27T09:47:56Z https://biopharmaperspective.com/wp-content/uploads/2026/07/cropped-bp-logo-1.png https://biopharmaperspective.com/2026/07/27/why-big-pharma-is-buying-biotech-again-the-patent-cliff-explained/ 2026-07-27T09:51:16Z https://biopharmaperspective.com/wp-content/uploads/2026/07/bp-image-1.png https://biopharmaperspective.com/2026/07/27/why-big-pharma-is-buying-biotech-again-the-patent-cliff-explained/ 2026-07-27T09:52:35Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260727_image1.png https://biopharmaperspective.com/2026/07/27/why-big-pharma-is-buying-biotech-again-the-patent-cliff-explained/ 2026-07-27T10:11:36Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260727_thumbnail.png https://biopharmaperspective.com/about/ 2026-07-28T10:32:00Z https://biopharmaperspective.com/wp-content/uploads/2026/07/bp-image-2.png https://biopharmaperspective.com/pharma-trends/ 2026-07-28T12:35:52Z https://biopharmaperspective.com/wp-content/uploads/2026/07/bp-image-3.png https://biopharmaperspective.com/2025/10/30/home/ 2026-07-28T12:42:08Z https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image.png https://biopharmaperspective.com/2025/10/30/home/ 2026-07-28T12:43:12Z https://biopharmaperspective.com/wp-content/uploads/2025/10/bp-image-1.png https://biopharmaperspective.com/hero-image/ 2026-07-28T12:50:39Z https://biopharmaperspective.com/wp-content/uploads/2026/07/hero-image.png https://biopharmaperspective.com/2026/07/28/why-astrazeneca-says-drug-development-must-move-at-chinese-speed/ 2026-07-28T13:01:32Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260728_image1.png https://biopharmaperspective.com/2026/07/28/why-astrazeneca-says-drug-development-must-move-at-chinese-speed/ 2026-07-28T13:16:13Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260728_thumbnail.png https://biopharmaperspective.com/2026/07/29/astrazeneca-keeps-its-80-billion-goal-despite-a-major-trial-setback/ 2026-07-29T14:57:05Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260729_thumbnail.png https://biopharmaperspective.com/2026/07/30/jj-takes-a-profit-hit-to-secure-an-in-vivo-car-t-platform/ 2026-07-30T10:08:25Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260730_image1.png https://biopharmaperspective.com/2026/07/30/jj-takes-a-profit-hit-to-secure-an-in-vivo-car-t-platform/ 2026-07-30T10:10:25Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260730_thumbnail.png https://biopharmaperspective.com/2026/07/31/sanofis-pipeline-reset-signals-a-new-era-of-rd-discipline/ 2026-07-31T10:49:57Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260731_image1.png https://biopharmaperspective.com/2026/07/31/sanofis-pipeline-reset-signals-a-new-era-of-rd-discipline/ 2026-07-31T10:52:12Z https://biopharmaperspective.com/wp-content/uploads/2026/07/20260731_thumbnail.png https://biopharmaperspective.com/2026/08/03/astrazeneca-and-bristol-myers-squibb-explore-a-400-billion-pharma-megadeal/ 2026-08-03T12:42:46Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260803.png https://biopharmaperspective.com/2026/08/03/astrazeneca-and-bristol-myers-squibb-explore-a-400-billion-pharma-megadeal/ 2026-08-03T12:55:19Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260803_thumbnail.png https://biopharmaperspective.com/2026/08/04/curium-to-acquire-lantheus-in-an-8-billion-radiopharma-deal/ 2026-08-04T14:23:31Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260804_image1.png https://biopharmaperspective.com/2026/08/04/curium-to-acquire-lantheus-in-an-8-billion-radiopharma-deal/ 2026-08-04T14:26:28Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260804_thumbnail.png https://biopharmaperspective.com/2026/08/05/jazz-to-withdraw-zepzelcas-second-line-sclc-indication-after-phase-3-failure/ 2026-08-05T12:02:51Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260805_image1.png https://biopharmaperspective.com/2026/08/05/jazz-to-withdraw-zepzelcas-second-line-sclc-indication-after-phase-3-failure/ 2026-08-05T12:08:26Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260805_thumbnail.png https://biopharmaperspective.com/2026/08/07/can-sionna-challenge-vertexs-cystic-fibrosis-empire/ 2026-08-07T10:38:08Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260807_1_image1.png https://biopharmaperspective.com/2026/08/07/can-sionna-challenge-vertexs-cystic-fibrosis-empire/ 2026-08-07T10:40:20Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260807_1_thumbnail.png https://biopharmaperspective.com/2026/08/07/tarsus-bets-up-to-800-million-on-a-deuterated-vitamin-a-drug/ 2026-08-07T10:41:43Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260807_2_image1.png https://biopharmaperspective.com/2026/08/07/tarsus-bets-up-to-800-million-on-a-deuterated-vitamin-a-drug/ 2026-08-07T10:45:18Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260807_2_thumbnail.png https://biopharmaperspective.com/2026/08/10/moderna-wins-fda-approval-for-the-first-mrna-flu-vaccine/ 2026-08-10T10:23:28Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260810_image1.png https://biopharmaperspective.com/2026/08/10/moderna-wins-fda-approval-for-the-first-mrna-flu-vaccine/ 2026-08-10T10:24:29Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260810_thumbnail.png https://biopharmaperspective.com/2026/08/11/jazz-bets-1-32-billion-on-a-precision-therapy-for-rare-epilepsy/ 2026-08-11T09:30:27Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260811_image1.png https://biopharmaperspective.com/2026/08/11/jazz-bets-1-32-billion-on-a-precision-therapy-for-rare-epilepsy/ 2026-08-11T09:31:54Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260811_Thumbnail.png https://biopharmaperspective.com/2026/08/12/epicrispr-raises-90-million-to-silence-disease-genes-without-cutting-dna/ 2026-08-12T10:46:27Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260812_image1.png https://biopharmaperspective.com/2026/08/12/epicrispr-raises-90-million-to-silence-disease-genes-without-cutting-dna/ 2026-08-12T10:47:48Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260812_Thumbnail.png https://biopharmaperspective.com/2026/08/13/why-astrazeneca-investors-rejected-a-400-billion-bms-megadeal/ 2026-08-13T11:13:59Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260813_image1.png https://biopharmaperspective.com/2026/08/13/why-astrazeneca-investors-rejected-a-400-billion-bms-megadeal/ 2026-08-13T11:15:18Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260813_Thumbnail.png https://biopharmaperspective.com/2026/08/15/bristol-myers-squibb-bms-wins-fda-approval-for-the-first-celmod-therapy-in-multiple-myeloma/ 2026-08-14T15:08:57Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260814_image1.png https://biopharmaperspective.com/2026/08/15/bristol-myers-squibb-bms-wins-fda-approval-for-the-first-celmod-therapy-in-multiple-myeloma/ 2026-08-14T15:10:04Z https://biopharmaperspective.com/wp-content/uploads/2026/08/20260814_Thumbnail.png